New drug before surgery could fight head and neck cancer
NCT ID NCT03565783
First seen Nov 10, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase II trial tests the drug cemiplimab, given before surgery, in 44 people with stage II-IV head and neck skin cancer that can be removed. The goal is to see if the drug helps shrink tumors and delays cancer from coming back. Cemiplimab works by helping the immune system attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemiplimab (a drug that helps the immune system fight cancer)
What this could lead to
If successful, this could show that giving cemiplimab before surgery helps shrink tumors and lowers the chance of cancer coming back.
What could go wrong
This is a small, early-phase trial with only 44 people. The drug may not work for everyone, and side effects from immunotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.